Next Article in Journal
The Dilemma of Cure and Damage in Oligodendroglioma: Ways to Tip the Balance Away from the Damage
Previous Article in Journal
Novel Agents for Acute Myeloid Leukemia
Previous Article in Special Issue
The Cooperative Relationship between STAT5 and Reactive Oxygen Species in Leukemia: Mechanism and Therapeutic Potential
Article Menu

Export Article

Open AccessReview
Cancers 2018, 10(11), 430;

Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia

Department of Pharmacy, University of Genova, Viale Benedetto XV 3, 16132 Genova, Italy
Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy
Author to whom correspondence should be addressed.
Received: 5 September 2018 / Revised: 24 October 2018 / Accepted: 7 November 2018 / Published: 9 November 2018
(This article belongs to the Special Issue Tyrosine Kinase Signaling Pathways in Cancer)
Full-Text   |   PDF [524 KB, uploaded 9 November 2018]   |  


Ponatinib is a third line drug for the treatment of chronic myeloid leukemia patients, especially those that develop the gatekeeper mutation T315I, which is resistant to the first and the second line drugs imatinib, nilotinib, dasatinib and bosutinib. The compound was first identified as a pan Bcr-Abl and Src kinase inhibitor. Further studies have indicated that it is a multitargeted inhibitor that is active on FGFRs, RET, AKT, ERK1/2, KIT, MEKK2 and other kinases. For this reason, the compound has been evaluated on several cancers in which these kinases play important roles, including thyroid, breast, ovary and lung cancer, neuroblastoma, rhabdoid tumours and in myeloproliferative disorders. Ponatinib is also being tested in clinical trials to evaluate its activity in FLT3-ITD acute myelogenous leukemia, head and neck cancers, certain type of lung cancer, gastrointestinal stromal tumours and other malignancies. In this review we report the most recent preclinical and clinical studies on ponatinib in cancers other than CML, with the aim of giving a complete overview of this interesting compound. View Full-Text
Keywords: ponatinib; protein kinase inhibitor; cancer ponatinib; protein kinase inhibitor; cancer

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Musumeci, F.; Greco, C.; Grossi, G.; Molinari, A.; Schenone, S. Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia. Cancers 2018, 10, 430.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top